PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
London S.E.
20:35:08 27/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 118.00 GBX | +3.51% |
|
+3.69% | -5.60% |
| 10-19 | PureTech Health to announce clinical trial results in Madrid | AN |
| 10-08 | Dillistone new strategy; Oriole Resources maiden MRE | AN |
| Market Cap | 385M 346M 319M 289M 541M 36.57B 547M 3.83B 1.52B 19.17B 1.45B 1.41B 60.78B | P/E 2026 * |
-3.32x | P/E 2027 * | -3.37x |
|---|---|---|---|---|---|
| Enterprise Value | 154M 138M 128M 116M 217M 14.65B 219M 1.53B 609M 7.68B 579M 567M 24.35B | EV / Sales 2026 * |
19.2x | EV / Sales 2027 * | 15.1x |
| Free-Float |
84.97% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| PRTC | Delayed | |
CBOE
| PRTC | Real-time | |
|
Xetra
| 0VQ | End-of-day quote | |
|
OTC Markets
| PTCH.F | Delayed | |
|
Deutsche Boerse AG
| 0VQ | Delayed | |
|
Börse Stuttgart
| 0VQ | Delayed |
Last Transcript: PureTech Health plc
| 1 day | +3.51% | ||
| 1 week | +3.69% | ||
| Current month | +2.61% | ||
| 1 month | +3.15% | ||
| 3 months | -3.28% | ||
| 6 months | -5.75% | ||
| Current year | -5.60% |
| 1 week | 110 |  | 119.26 |
| 1 month | 106.6 | | 119.26 |
| Current year | 106.6 | | 143.6 |
| 1 year | 106.6 | | 143.6 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 375.5 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/03/26 | Buy | Founder | 112,509 | 0.0466% | ||
| 24/09/25 | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 24/09/25 | Buy | Director | 29,239 | 0.0122% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.51% | +3.69% | -12.33% | -24.55% | 373M | |
| -3.10% | -4.19% | +32.67% | +59.47% | 65.28B | |
| +0.33% | +0.33% | +10.16% | +78.07% | 54.57B | |
| +0.16% | +1.73% | +9.89% | +102.10% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 45.03B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 42.17B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.42B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.71B | |
| +1.11% | +15.18% | +60.27% | +49.33% | 26.5B | |
| +1.97% | -7.77% | +23.94% | -9.78% | 24.01B | |
| Average | +0.25% | +0.22% | +39.77% | +136.56% | 38.36B | |
| Weighted average by Cap. | -0.42% | -0.58% | +42.38% | +153.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.02M 7.2M 6.64M 6.02M 11.26M 761M 11.4M 79.65M 31.63M 399M 30.09M 29.45M 1.27B | 14.23M 12.77M 11.79M 10.69M 19.99M 1.35B 20.23M 141M 56.15M 708M 53.41M 52.27M 2.25B |
| Net income | -135M -121M -112M -101M -189M -12.79B -191M -1.34B -531M -6.7B -505M -495M -21.26B | -119M -107M -98.66M -89.46M -167M -11.31B -169M -1.18B -470M -5.93B -447M -437M -18.8B |
| Net Debt | -231M -207M -191M -173M -324M -21.92B -328M -2.29B -911M -11.49B -866M -848M -36.43B | -170M -153M -141M -128M -239M -16.18B -242M -1.69B -672M -8.48B -639M -626M -26.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/10/26 | GBX 118.00 | +3.51% | 609,314 |
| 26/10/26 | GBX 114.00 | +3.64% | 474,538 |
| 23/10/26 | GBX 110.00 | -5.01% | 265,772 |
| 22/10/26 | GBX 115.80 | +1.22% | 148,694 |
| 21/10/26 | GBX 114.40 | +0.53% | 172,889 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
